RenovoRx, Inc.

RenovoRx, Inc. announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23, 2026. He will discuss the company's record first quarter 2026 revenue of $563,000, driven by growing demand for RenovoCath, and the expected completion of enrollment in its Phase III TIGeR-PaC clinical trial by the end of June 2026. Mr. Bagai will also provide updates on the trial's progress and the recent FDA Orphan Drug Designation for oxaliplatin for pancreatic cancer, which is the company's third overall ODD.

RenovoRx, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for oxaliplatin for the treatment of pancreatic cancer. This is the company's second ODD in pancreatic cancer and third overall, underscoring its targeted intra-arterial drug-delivery approach using the RenovoCath device. The ODD provides significant regulatory and financial benefits, including seven years of market exclusivity upon FDA approval, a 25% federal tax credit on clinical research expenses, and a waiver of FDA application fees. RenovoRx continues to advance its therapeutic pipeline, including the Phase III TIGeR-PaC trial, and expand commercialization of RenovoCath.

RenovoRx announced the online publication of an abstract from a sub-study of its Phase III TIGeR-PaC clinical trial, ahead of the 2026 ASCO Annual Meeting. The sub-study supports the Trans-Arterial Micro-Perfusion (TAMP) platform for targeted intra-arterial delivery of gemcitabine, demonstrating potential to increase local drug potency and reduce systemic exposure and common side effects. Results showed a direct correlation between increased metabolite levels and reduced CA 19-9, a biomarker for chemotherapy response. The company also noted RenovoCath sales of $1.1 million in 2025 and $563,000 in Q1 2026, and anticipates full enrollment in the TIGeR-PaC trial by June 2026.

RenovoRx announced that its CEO and CFO will participate in the Alliance Global Partners Annual Healthcare Company Showcase on May 20, 2026. They will discuss record first-quarter 2026 revenue of $563,000 from RenovoCath sales, accelerating adoption, and growing repeat orders. The company also expects to close enrollment for its Phase III TIGeR-PaC clinical trial in early June, completing the milestone by the end of June 2026, with final data anticipated in mid to late 2027. Additionally, they will highlight support for investigator-initiated trials and post-marketing registry studies.

RenovoRx, Inc. filed an amendment to its 2025 Form 10-K to revise risk factor disclosures related to previously identified material weaknesses in internal control over financial reporting. The company announced that these material weaknesses were remediated as of December 31, 2025, and management confirmed the effectiveness of its internal control over financial reporting. Despite this improvement in controls, RenovoRx continues to face significant financial challenges, including substantial net losses and the ongoing need for additional capital to fund its development and commercialization efforts.

RenovoRx reported a significant increase in Q1 2026 revenue, reaching $563,000, up 186% year-over-year, driven by accelerated commercial rollout of RenovoCath. The company expanded its active commercial cancer centers to 16 and expects to close enrollment for its Phase III TIGeR-PaC trial by the end of June 2026. Despite revenue growth, net loss widened to $3.5 million, and cash used in operations increased, though the company believes current cash is sufficient for at least the next 12 months.

RenovoRx reported record first-quarter 2026 financial results, with revenue reaching $563,000, a 136% increase quarter-over-quarter and exceeding 50% of full-year 2025 revenue. The company expanded its active commercial cancer center customers to 16 and expects full enrollment for its Phase III TIGeR-PaC trial in June 2026. RenovoRx also strengthened its balance sheet with $12.4 million in cash, sufficient to fund operations into at least the second half of 2027, partly due to a $10 million private placement. The company reiterated its full-year 2026 revenue guidance of $3 million to $4 million.

RenovoRx, Inc. announced its 2026 Annual Meeting of Stockholders will be held on June 30, 2026. Stockholders will vote on the election of six directors, an amendment to the 2021 Omnibus Equity Incentive Plan to add 2,000,000 shares (4.4% of outstanding shares), and the ratification of Frank, Rimerman + Co. LLP as the independent auditor for the year ending December 31, 2026. The Board unanimously recommends voting "FOR" all proposals.

RenovoRx, Inc. (RNXT) announced it will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET. Management is expected to discuss positive commercial momentum for RenovoCath sales, including increased presence in high-volume institutions and rising repeat orders. The company will also provide an update on its clinical program developments, including the Phase III TIGeR-PaC trial, which is nearing full enrollment and remains on track for completion in the first half of 2026, with final data anticipated in 2027.

RenovoRx announced positive clinical data for its TAMP (Trans-Arterial Micro-Perfusion) therapy platform in locally advanced pancreatic cancer (LAPC), presented at the 2026 SIR Annual Scientific Meeting. The data indicated TAMP is a promising approach for localized chemotherapy delivery, showing reduced systemic toxicity and notable reductions in tumor activity via metabolic imaging. These findings suggest a potential treatment response and may complement the company's ongoing Phase III TIGeR-PaC clinical trial.